MedTrace Logo

A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults

NCT06375772 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-11-19

No results posted yet for this study

Summary

2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study to investigate the efficacy and safety of 2-Deoxy-D-Glucose as a pre-exposure prophylaxis using the rhinovirus challenge model in healthy study participants.

Conditions

  • Acute Nasopharyngitis

Interventions

DRUG

2-Deoxy-D-glucose

Intranasal administration

OTHER

Placebo

Intranasal administration

Sponsors & Collaborators

  • G.ST Antivirals GmbH

    lead INDUSTRY

Principal Investigators

  • Ingrid de Visser-Kamerling, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2024-08-13
Completion
2024-08-13

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06375772 on ClinicalTrials.gov